Novo Nordisk’s weekly growth hormone Sogroya receives FDA approval for Turner syndrome

The U.S. FDA approved Novo Nordisk’s once‑weekly growth hormone Sogroya for children aged 2.5 years and older with Turner syndrome. The approval is based on the phase‑3 REAL8 trial, which enrolled 105 treatment‑naïve pediatric patients and compared 68 patients receiving Sogroya 0.24 mg/kg/week with 37 receiving daily somatropin 0.05 mg/kg/day. At week 52, the weekly arm grew an average of 8.9 cm per year versus 9.7 cm for the daily arm, a difference of 0.8 cm per year.

The approval adds a new indication for Sogroya, expanding Novo Nordisk’s growth‑hormone portfolio and creating a potential revenue stream. However, the trial showed a modest annual growth shortfall versus daily therapy, which may temper market enthusiasm and affect prescribing decisions.

  • 1The FDA approved Sogroya on 20 Nov 2026 for children 2.5 years and older with Turner syndrome.
  • 2The REAL8 trial enrolled 105 pediatric patients aged 2.5‑10 years with Turner syndrome.
  • 368 patients received Sogroya 0.24 mg/kg/week; 37 patients received daily somatropin 0.05 mg/kg/day.
  • 4At week 52, the weekly arm grew 8.9 cm (3.5 in) per year; the daily arm grew 9.7 cm (3.8 in) per year, a gap of 0.8 cm (0.3 in) per year.
  • 5The FDA label lists a 95 % confidence interval for the treatment difference of –1.58 cm to 0.07 cm per year.
  • 6The daily dose used (0.05 mg/kg/day) is below the U.S. maximum approved dose of 0.067 mg/kg/day for pediatric Turner syndrome.
  • Material 2 reports two different 95 % confidence intervals for the growth difference (text: –1.58 to 0.07 cm; table: –1.57 to –0.11 cm).

Sources